Pericardium Diseases: Increasing Incidence of Heart Attack is Projected to Encourage The Growth of The Global Pericardium Diseases Market at a CAGR of 8.2% During Forecasted Period 2017-2023 :

Pune, India, December 2017 /MRFR Press Release/- Market Research Future published a half-cooked research report on global pericardium diseases market. 

Market Highlights

During the last few years, a drastic increase in the number of patients suffering from heart and cardiovascular diseases has been observed. The pericardium is a double-layered, collagenous membrane that surrounds the heart and helps to protect the heart from external shock. According to the Health Grades Inc., 1 in every 2,000 individual suffers from pericarditis. The global pericardium diseases market is majorly driven by increasing prevalence of pericardium diseases. Additionally, increasing healthcare expenditure, rising number of patients suffering from heart diseases and increasing demand for the better treatment is expected to fuel the growth of the market over the corresponding period. On the other hand, the high cost of the treatment and devices may slow the growth of the market.

The global pericardium diseases market is expected to grow at a CAGR of 8.2% during the forecast period 2017-2023. 


The global pericardium diseases market is segmented on the basis of types, treatment, and end users.

On the basis of the types, the market is segmented into acute pericarditis, hemopericardium, pericarditis, tuberculous pericarditis, and others.

On the basis of the treatment, the market is segmented into diagnostic test, and disease treatment. The diagnostic treatment is further segmented into the physical exam, EKG, chest X-ray, echocardiography, cardiac CT, cardiac MRI, and others. The diseases treatment is sub-segmented into anti-inflammatory drugs, pericardium patches, surgery, and others.

On the basis of the end users, the market is segmented into hospital & clinics, ambulatory centers, and others

Regional Analysis

The Americas dominate the global market owing to a huge population suffering from pericardium diseases, strong government support for research & development and high health care spending. According to the Centers for Disease Control and Prevention (2014), over 610,000 people die due to heart disease in the U.S. every year. Increasing prevalence of the disease has boosted the market growth in America. Additionally, changing lifestyle and increasing smoking addiction further fuelling the growth of the market. 

Europe is the second leading global market, which is followed by Asia Pacific. Asia Pacific is the fastest growing market. Its growth is majorly driven by India, China, and Japan owing to a huge number of patients and rapidly growing economy. Governments in Asia Pacific region are supporting manufacturers for research & development, which can serve as a path for the development of the market.

The Middle East and African region contribute the least to the growth of the global market. The Middle East dominates region owing to the presence of the UAE, Saudi Arabia, and Kuwait. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition of the region. However, the growth of the African market is high due to the presence of opportunities for the development of the market. 

Key Players

Some of key the players in the market are Smith and Nephew (U.K), Teva Pharmaceutical (Isreal), GlaxoSmithKline Plc. (U.K), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), Arthrex, Inc.(U.S.), Medtronic (U.K), Edwards Lifesciences (U.S.), Abbott Laboratories (U.S.), Johnson & Johnson Services, Inc. (U.S.), C.R. Bard Inc (U.S.)Allergan (U.S.), Integra Lifesciences (U.S.), Livanova(U.K), and Zimmer Biomet (U.S.)

Access Report Details @